Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Dexcom (DXCM) Long-Term Debt Repayments (2016 - 2023)

Dexcom has reported Long-Term Debt Repayments over the past 6 years, most recently at $136.8 million for Q4 2023.

Quarterly Long-Term Debt Repayments changed N/A to $136.8 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $136.8 million through Dec 2024, changed 0.0% year-over-year, with the annual reading at $787.3 million for FY2023, N/A changed from the prior year.
Long-Term Debt Repayments was $136.8 million for Q4 2023 at Dexcom, up from $75.0 million in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $136.8 million in Q4 2023 and troughed at $136.8 million in Q4 2023.